Enabling drug discovery through

cutting-edge AI technologies



To be a global leader integrating biopharma and AI



To build a healthier world and to make innovative medicines accessible

About Us

Founded in 2019, Galixir is a company dedicated to applying cutting-edge artificial intelligence technologies to empower drug discovery

Integrating tools and experience of computational chemistry, medicinal chemistry and biology, Galixir leverages cutting-edge AI algorithms to resolve problems in preclinical development of small molecule drugs and find candidate molecules with high potency, good druggability and novel structures.

Galixir is collaborating with MNCs, leading domestic pharmaceutical companies, biotech companies on developing pipelines on therapeutic areas including central nervous system diseases, autoimmune diseases, tumors, respiratory diseases. We have made good progress in both inhibitor development and agonist development. By greatly lowering the cost and time of preclinical drug discovery, Galixir makes it possible to develop multiple drug discovery pipelines concurrently and optimize the overall strategic layout.

About UsAbout Us

Our Team Members

are from worldwide top-tier universities, first-rate Internet companies and renowned pharmaceutical enterprises

Galixir team members have rich experience in leading drug discovery projects to IND and FDA approval, and machine learning application experience in top-tier Internet companies including Google, Apple and Microsoft. Besides, Galixir has already published nearly 20 papers in top journals and conference proceedings, covering subjects including molecular generation, property prediction and virtual screening and so forth. And our models have kept the world performance record.

Galixir works together with domestic and oversea universities and research institutions including Georgia Institute of Technology, Massachusetts Institute of Technology, University of Pennsylvania, Google Brain of Google AI, Mila, Guangzhou Institutes of Biomedicine and Health of Chinese Academy of Science, Institute of Microbiology of Chinese Academy of Science, Shanghai Jiao Tong University, Zhejiang University and Sun Yat-sen University.

Our History

Galixir is founded
Become a member of Merck China Innovation Hub
Close Series Seed financing with lead investor Gaorong Capital
Become a strategic partner of a China's listed pharmaceutical company
Close Series Pre-A financing with lead investors Sourcecode Capital and DCM Capital
Start collaboration with more leading pharmaceutical companies
Start collaboration with biotechnology innovation companies
Close Series A/A+ financing with lead investors Redpoint China Ventures and 5Y Capital
Become a strategic partner of two multinational pharmaceutical companies
Set up Shanghai Office
Close a round of strategic financing with lead investor Shanghai AI Industry Investment Fund
Start pipeline collaboration with many top biopharmaceutical companies


  • 中山大学
  • 源码资本
  • 高榕资本
  • DCM
  • 五源资本
  • 5
  • Bioduro


Galixir joins hands with our partners from circles of academy,industry and investment to boost the digitalization and intelligence of new drug discoveryand write a new chapter for drug discoveryAnd more undisclosed partners......